Hematopoiesis News Volume 12.07 | March 2 2021

    By
    Justin.choi
    -
    0
    20







    2021-03-01 | HEMA 12.07


    Hematopoiesis News by STEMCELL Technologies
    Vol. 12.07 – 2 March, 2021
    TOP STORY

    Increased Stem Cell Proliferation in Atherosclerosis Accelerates Clonal Hematopoiesis

    Scientists showed that HSC division rates were increased in mice and humans with atherosclerosis. Mathematical analysis demonstrated that increased stem cell proliferation expedited somatic evolution and expansion of clones with driver mutations.
    [Cell]

    Abstract
    Explore scientific events this March with the Science Events Calendar.
    PUBLICATIONSRanked by the impact factor of the journal

    TWIST1 Preserves Hematopoietic Stem Cell Function via CACNA1B/Ca2+/Mitochondria Axis

    The authors demonstrated that Twist1 deletion resulted in a significantly decreased lymphoid-biased HSC frequency, markedly reduced HSC dormancy and self-renewal capacities, and skewed myeloid differentiation in steady-state hematopoiesis.
    [Blood]

    Abstract

    Functional Reconstruction of Human AML Reveals Stem Cell Origin and Vulnerability of Treatment-Resistant MLL-Rearranged Leukemia

    HSC-derived mixed lineage leukemia-acute myeloid leukemia gene fusions was highly resistant to chemotherapy and expressed elevated amounts of the multispecific anion transporter ABCC3.
    [Science Translational Medicine]

    AbstractPress Release

    Excessive R-Loops Trigger an Inflammatory Cascade Leading to Increased HSPC Production

    Researchers identified DEAD-box helicase 41 as a gatekeeper of hematopoietic stem and progenitor cell (HSPC) production. Using zebrafish ddx41 mutants, they unveiled a critical role for this helicase in regulating HSPC production at the endothelial-to-hematopoietic transition.
    [Developmental Cell]

    Full ArticleGraphical Abstract

    Siglec-6 Is a Target for Chimeric Antigen Receptor T-Cell Treatment of Chronic Lymphocytic Leukemia

    Researchers evaluated CAR-T cells specific for Siglec-6, an antigen expressed in chronic lymphocytic leukemia (CLL), as a novel CAR-T cell treatment for CLL.
    [Leukemia]

    Abstract

    Genome Editing of Donor-Derived T-Cells to Generate Allogenic Chimeric Antigen Receptor-Modified T Cells: Optimizing αβ T Cell-Depleted Haploidentical Hematopoietic Stem Cell Transplantation

    Using genome editing with Cas9 ribonucleoprotein and adeno-associated virus serotype 6, the authors integrated a CD19-specific chimeric antigen receptor in-frame into the TRAC locus.
    [Haematologica]

    Full Article

    Bortezomib Suppresses Self-Renewal and Leukemogenesis of Leukemia Stem Cells by NF-ĸB-Dependent Inhibition of CDK6 in MLL-Rearranged Myeloid Leukemia

    Investigators found that bortezomib (bort) suppressed cell proliferation and decreased colony formation in human and murine leukemic blasts. Bort reduced the frequency and function of leukemia stem cells, inhibited the progression, and extended the overall survival in mixed‐lineage leukemia‐AF9‐transformed leukemic mice.
    [Journal of Cellular and Molecular Medicine]

    Full Article

    Flow Cytometric Immunophenotypic Alterations of Persistent Clonal Hematopoiesis in Remission Bone Marrows of Patients with NPM1-Mutated Acute Myeloid Leukemia

    From a consecutive cohort of 67 patients with nucleophosmin 1‐mutated (NPM1mut) acute myeloid leukemia, scientists identified 50 who achieved NPM1mut clearance and had parallel multicolor flow cytometry and next generation sequencing.
    [British Journal of Haematology]

    Abstract

    Lymphohematopoietic Graft-versus-Host Responses Promote Mixed Chimerism in Patients Receiving Intestinal Transplantation

    Researchers demonstrated that patients with macrochimerism had high graft-versus-host to host-versus-graft T cell clonal ratios in their allografts.
    [European Journal of Clinical Investigation]

    AbstractFull ArticleGraphical Abstract

    Request your free copy of the 'Bone Marrow Niches and HSC Fates' Wallchart
    REVIEWS

    Potential Targeting of FLT3 Acute Myeloid Leukemia

    The authors review the rationale for targeting the FLT3 receptor in acute myeloid leukemia (AML), the impact of FLT3 mutation on patient prognosis, the current standard of care approaches to FLT3-mutated AML management, and the diverse array of FLT3 inhibitors in use and under investigation.
    [Haematologica]

    Full Article

    The Application of BH3 Mimetics in Myeloid Leukemias

    As the number and variety of available BH3 mimetics increases, and investigations into applying these novel inhibitors to treat myeloid leukemias continue apace the need to evaluate where the science currently stands in this rapidly expanding field is clear.
    [Cell Death & Disease]

    Full Article

    Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

    Scientists discuss their approach to relapsed or refractory diffuse large B cell lymphoma patients and the open question of optimal sequencing of autologous transplant , CAR-T therapy, and bispecific antibodies.
    [Current Hematologic Malignancy Reports]

    Abstract
    INDUSTRY AND POLICY NEWS

    National Marrow Donor Program/Be The Match Announce Plan to Launch ACCESS Clinical Trial

    The National Marrow Donor Program®/Be The Match® announced plans to launch the ACCESS clinical trial titled “A Multicenter Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies.”
    [The National Marrow Donor Program®]

    Press Release

    Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia

    BeiGene, Ltd. announced that BRUKINSA® has been approved by Health Canada for the treatment of adult patients with Waldenström’s macroglobulinemia.
    [BeiGene, Ltd.]

    Press Release
    FEATURED EVENT

    Cancer Stem Cells: Advances in Biology and Clinical Translation

    May 19 – 21, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Fellow – Myeloid-Derived Suppressor Cells

    Houston Methodist Research Institute – Houston, Texas, United States

    Postdoctoral Position – Hematopoietic Development

    Icahn School of Medicine at Mount Sinai – New York, New York, United States

    Postdoctoral Associate – Normal and Abnormal Hematopoiesis

    University of Pittsburgh School of Medicine – Pittsburgh, Pennsylvania, United States

    Postdoctoral Positions – Hematopoiesis, Leukemia, Cancer, Human Pluripotent Stem Cells

    Icahn School of Medicine at Mount Sinai – New York, New York, United States

    Training Fellowships – Glycosciences

    Blood Research Institute – Milwaukee, Wisconsin, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter